LOGIN  |  REGISTER
Terns Pharmaceuticals
Terns Pharmaceuticals

Mettler-Toledo to Present at the 43rd Annual J.P. Morgan Healthcare Conference

December 20, 2024 | Last Trade: US$1,335.29 10.61 0.80

COLUMBUS, Ohio / Dec 20, 2024 / Business Wire / Mettler-Toledo International Inc. (NYSE: MTD) today announced it will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 14, 2025 at 3:45 p.m. Pacific Time. A live webcast of the presentation will be available on the Company’s investor relations website at investors.mt.com.

METTLER TOLEDO (NYSE: MTD) is a leading global supplier of precision instruments and services. We have strong leadership positions in all of our businesses and believe we hold global number-one market positions in most of them. We are recognized as an innovation leader and our solutions are critical in key R&D, quality control, and manufacturing processes for customers in a wide range of industries including life sciences, food, and chemicals. Our sales and service network is one of the most extensive in the industry. Our products are sold in more than 140 countries and we have a direct presence in approximately 40 countries. With proven growth strategies and a focus on execution, we have achieved a long-term track record of strong financial performance. For more information, please visit www.mt.com.

Chimerix

Stock Quote

Last Trade: US$1,335.29
Daily Change: 10.61 0.80
Daily Volume: 72,611
Market Cap: US$28.170B

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page